This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Pirfenidone (Esbriet®) was the first anti-fibrotic approved for IPF (Japan 2008; EU 2011; US 2014), and for over a decade it shared a comfortable duopoly with Nintedanib (Ofev®, Boehringer Ingelheim). That era is now ending. In October 2025, Boehringer Ingelheim’s Nerandomilast (PDE4B inhibitor) received approval — the first new IPF mechanism approved in over a decade — directly challenging both incumbents with Phase 3 data showing FVC decline of −106 to…
Author: Eureka LS
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. The MSLN (Mesothelin) target space is one of the most active and rapidly evolving frontiers in solid tumor oncology, with 214 drugs in the global pipeline, 151 registered clinical trials, and 82 published trial results identified in this analysis. The field is dominated by cell therapies (CAR-T/CAR-NK) and ADCs, with no approved drugs yet — making it a high-opportunity, high-competition arena. Chinese biotech players have emerged as particularly prolific contributors, especially in CAR-T…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Prostate cancer remains one of the most commercially active and therapeutically complex oncology indications, with 1,682 drugs in development (roll-up) across its subtypes. The landscape is defined by a dominant androgen receptor (AR) signaling axis, an increasingly important precision oncology layer (PARP inhibitors, PSMA-targeted radioligand therapy), and a rapidly evolving pipeline of next-generation modalities including AR degraders (PROTACs), T-cell engagers, and alpha-emitter radiopharmaceuticals. The competitive field is highly concentrated around Johnson…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract HER2 (ERBB2/ErbB-2) remains one of the most commercially important and scientifically active oncology targets, with 978 drugs in the database (roll-up), 48 approved agents, and over 392 active Phase 3 trials as of May 2026. The competitive center of gravity has decisively shifted toward antibody-drug conjugates (ADCs) — particularly trastuzumab deruxtecan (T-DXd) — while a second wave of Chinese-originating ADCs and selective HER2 TKIs is rapidly challenging the Western incumbents. The indication…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. The TSLP competitive landscape is one of the most active in respiratory and atopic disease biology. The space is dominated by AstraZeneca/Amgen’s approved Tezepelumab (Tezspire) — the only approved anti-TSLP therapy — while a wave of challengers from both Western and Chinese biotechs are advancing through Phase 2/3. The arena has seen over $5B in deal activity since 2021, signaling strong commercial conviction in the target. Abstract TSLP (Thymic Stromal Lymphopoietin) is an…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. The TIGIT competitive landscape is one of the most active and consequential battlegrounds in immuno-oncology. With 131 drugs in the database targeting TIGIT (81 in active development), the field has undergone a dramatic reset: a wave of Phase 3 failures from the first-generation mono-antibody approach has thinned the herd, while AstraZeneca’s bispecific PD-1×TIGIT antibody Rilvegostomig has emerged as the new leader with multiple positive Phase 3 readouts. The arena is now bifurcating between…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The colorectal cancer (CRC) therapeutic landscape is undergoing a structural shift from broad chemotherapy backbones toward molecularly stratified precision therapies. The arena is highly active: 331 approved drugs (across all lines/indications), 142 in Phase 3, and 317 in Phase 2 are indexed against CRC. Three dominant technology routes define the competitive frontier — VEGF/angiogenesis inhibition (Roche/Genentech-led), KRAS G12C inhibition (Amgen, BMS/Mirati, and a cluster of Chinese biotechs), and PD-1/checkpoint immunotherapy (Merck,…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. 1. Target Overview c-Met (MET proto-oncogene, receptor tyrosine kinase; UniProt P08581; HGNC 7029) is a receptor tyrosine kinase that, upon binding its ligand hepatocyte growth factor (HGF), triggers downstream RAS-ERK, PI3K-AKT, and PLCγ-PKC cascades. These pathways drive proliferation, survival, invasion, angiogenesis, and epithelial-to-mesenchymal transition (EMT). In cancer, MET is aberrantly activated through: The database records 374 drugs associated with c-Met, of which 263 are in active development across 462 disease associations, underscoring its…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary CD19 is the most clinically validated B-cell antigen in oncology and immunology. As of May 2026, the target has generated 16 approved drugs globally — more than any other immune-oncology target outside PD-1/PD-L1 — and supports a pipeline of 240+ additional assets across all phases. The field has evolved through three distinct eras: naked antibodies (blinatumomab, 2014), autologous CAR-T (2017–2021), and a current wave of next-generation modalities including allogeneic CAR-T, bispecific…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Here is a comprehensive competitive landscape report for Ulcerative Colitis (UC), synthesized from 480+ drugs in development, 74 active Phase 3 trials, deal intelligence, clinical guidelines, and translational research data. Executive Summary Ulcerative Colitis is one of the most commercially active inflammatory bowel disease (IBD) indications globally, with 480+ drugs in development and 137 approved agents across multiple drug classes. The landscape has undergone a structural transformation over the past five years, shifting…